Over Karsinomlarında Östrojen, Progesteron Reseptörleri, C-Erb B-2, P53 ve BRCA1’in İmmünhistokimyasal Ekspresyonu ve Prognostik Önemleri
Open Access
- 21 March 2022
- journal article
- research article
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 17 (1) , 121-129
Abstract
Our study aimed to determine immunohistochemical expression of ER, PR, C-erbB-2, p53 and BRCA1 genes and their relationship with clinicopathological features and prognostic significance. The present study included 85 patients that were diagnosed with epithelial OC, treated and followed-up between 2002 and 2012 at Mersin University, Faculty of Medicine. Immunohistochemical expression of ER, PR, C-erbB-2, p53 and BRCA1 and their relation-ship with clinicopathological parameters were evaluated. In serous carcinomas, expression of ER was significantly associated with metastasis to the fallopian tube, expression of PR was significantly associated with patient’s age, expression of p53 was significantly associated with the progression-free survival (PFS), cytoplasmic expression of BRCA1 was significantly associated with the overall survival (OS) and PFS. In pathogenesis groups, 55 tumors were type 1, and 30 tumors were type 2. There were significant correlations with ER, PR and p53 expressions between the two groups. In our study, PR and p53 were prognostic factors in serous carcinoma. Extensive studies that contain more cases in each histological group are needed to determine the prognostic value of these five immunohistochemical markers.Keywords
Funding Information
- Mersin Üniversitesi, BAP bİRİMİ (BAP-TF CTB (DG) 2013-3 TU.)
This publication has 21 references indexed in Scilit:
- BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group StudyBritish Journal of Cancer, 2013
- Mutant p53: one name, many proteinsGenes & Development, 2012
- Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesisPathology, 2011
- Prognostic Impact of Concomitant p53 and PTEN on Outcome in Early Stage (FIGO I-II) Epithelial Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancerBritish Journal of Cancer, 2008
- Prognostic factors for high‐risk early‐stage epithelial ovarian cancerCancer, 2008
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum ResistanceCancer Research, 2008
- Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of PatientsJournal of Histochemistry & Cytochemistry, 2007
- Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic studyInternational Journal of Gynecological Cancer, 2005
- Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinomaCancer, 2003